Skip to main content
Erschienen in: European Journal of Pediatrics 11/2015

01.11.2015 | Short Communication

Skeletal and cardiac muscle involvement in children with glycogen storage disease type III

verfasst von: Engy A. Mogahed, Marian Y. Girgis, Rodina Sobhy, Hala Elhabashy, Osama M. Abdelaziz, Hanaa El-Karaksy

Erschienen in: European Journal of Pediatrics | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Glycogen storage disease type III (GSD III) may present with hepatic disease or may involve both skeletal and cardiac muscles as well. To assess the prevalence of neuromuscular and cardiac involvement in a group of children with GSD III, 28 children with GSD III, diagnosed by enzymatic assay, were enrolled in the study after an informed consent was obtained from their parents/guardians and after the study protocol was approved by our institutional ethical committee. Their mean age was 6.6 + 3.1 years. All cases were assessed neurologically by clinical examination, electromyography (EMG), and nerve conduction velocity. The heart was examined clinically by electrocardiogram and echocardiography. Seventeen patients (61 %) had myopathic changes by EMG, three of them had associated neuropathic changes. Creatine phosphokinase (CPK) was elevated in all myopathic cases except one. Children with myopathic changes were significantly older (p = 0.02), and CPK was significantly higher (p < 0.0001). Nine cases had left ventricular (LV) hypertrophy, seven of them had myopathic changes by EMG.
Conclusion: Myopathic changes are not uncommon in children with GSD III. Myopathic changes tend to occur in older age and are associated with higher CPK level. Cardiac muscle involvement is less common in this age group and may, on occasion, occur alone without skeletal muscle involvement. Despite mild degrees of affection in this age group, it is recommended to perform prospective annual screening using EMG and echocardiography in order to augment dietary therapy regimen to prevent progression to life threatening complications.
What is known:
•Neuromuscular involvement in GSD III occurs with advancing age.
What is new:
•Neuromuscular involvement in children with GSD III is not uncommon, being present in 60% of our cases.
•Cardiac muscle involvement in GSD III in children is less common and mostly asymptomatic.
Literatur
1.
Zurück zum Zitat Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K (1997) Specific heart muscle disease associated with glycogen storage disease type III: Clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 18:532–533CrossRefPubMed Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K (1997) Specific heart muscle disease associated with glycogen storage disease type III: Clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 18:532–533CrossRefPubMed
2.
Zurück zum Zitat Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, Kishnani PS (2012) Cardiac pathology in glycogen storage disease type III. JIND Rep 118:65–72 Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, Kishnani PS (2012) Cardiac pathology in glycogen storage disease type III. JIND Rep 118:65–72
3.
Zurück zum Zitat Chen YT, Kishnani PS, Leonard JV, Deanfield J (2009) Glycogen storage diseases. In: Valle D, Beaudet A, Vogelstein B et al (eds) Scriver’s online metabolic & molecular bases of inherited disease. McGraw-Hill, New York Chen YT, Kishnani PS, Leonard JV, Deanfield J (2009) Glycogen storage diseases. In: Valle D, Beaudet A, Vogelstein B et al (eds) Scriver’s online metabolic & molecular bases of inherited disease. McGraw-Hill, New York
4.
Zurück zum Zitat Coleman RA, Winter HS, Wolf B, Chen YT (1992) Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 15:869–881CrossRefPubMed Coleman RA, Winter HS, Wolf B, Chen YT (1992) Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 15:869–881CrossRefPubMed
5.
Zurück zum Zitat Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992) Glycogen storage disease type III (glycogen debranching enzyme deficiency): Correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 116:896–900CrossRefPubMed Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992) Glycogen storage disease type III (glycogen debranching enzyme deficiency): Correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 116:896–900CrossRefPubMed
6.
Zurück zum Zitat Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS (2010) The electrodiagnostic characteristics of glycogen storage disease type III. Genet Med 12:440–445CrossRefPubMed Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS (2010) The electrodiagnostic characteristics of glycogen storage disease type III. Genet Med 12:440–445CrossRefPubMed
8.
Zurück zum Zitat Momoi T, Sano H, Yamanaka C, Sasaki H, Mikawa H (1992) Glycogen storage disease type III with muscle involvement: Reappraisal of phenotypic variability and prognosis. Am J Med Genet 42:696–699CrossRefPubMed Momoi T, Sano H, Yamanaka C, Sasaki H, Mikawa H (1992) Glycogen storage disease type III with muscle involvement: Reappraisal of phenotypic variability and prognosis. Am J Med Genet 42:696–699CrossRefPubMed
9.
Zurück zum Zitat Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV (1984) Cardiac involvement in glycogen storage disease III: Morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 53:980–981CrossRefPubMed Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV (1984) Cardiac involvement in glycogen storage disease III: Morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 53:980–981CrossRefPubMed
10.
Zurück zum Zitat Preisler N, Pradel A, Husu E, Madsen KL, Becquemin MH, Mollet A, Labrune P, Petit F, Hogrel JY, Jardel C, Maillot F, Vissing J, Laforêt P (2013) Exercise intolerance in glycogen storage disease type III: Weakness or energy deficiency? Mol Genet Metab 109:14–20CrossRefPubMed Preisler N, Pradel A, Husu E, Madsen KL, Becquemin MH, Mollet A, Labrune P, Petit F, Hogrel JY, Jardel C, Maillot F, Vissing J, Laforêt P (2013) Exercise intolerance in glycogen storage disease type III: Weakness or energy deficiency? Mol Genet Metab 109:14–20CrossRefPubMed
11.
Zurück zum Zitat Seifert BL, Snyder MS, Klein AA, O'Loughlin JE, Magid MS, Engle MA (1992) Development of obstruction to ventricular outflow and impairment of inflow in glycogen storage disease of the heart: serial echocardiographic studies from birth to death at 6 months. Am Heart J 123:239–242CrossRefPubMed Seifert BL, Snyder MS, Klein AA, O'Loughlin JE, Magid MS, Engle MA (1992) Development of obstruction to ventricular outflow and impairment of inflow in glycogen storage disease of the heart: serial echocardiographic studies from birth to death at 6 months. Am Heart J 123:239–242CrossRefPubMed
12.
Zurück zum Zitat Vertilus SM, Austin SL, Foster KS, Boyette KE, Bali D, Li JS, Kishnani PS, Wechsler SB (2010) Echocardiographic manifestations of glycogen storage disease III: Increase in wall thickness and left ventricular mass over time. Genet Med 12:413–423PubMedCentralCrossRefPubMed Vertilus SM, Austin SL, Foster KS, Boyette KE, Bali D, Li JS, Kishnani PS, Wechsler SB (2010) Echocardiographic manifestations of glycogen storage disease III: Increase in wall thickness and left ventricular mass over time. Genet Med 12:413–423PubMedCentralCrossRefPubMed
Metadaten
Titel
Skeletal and cardiac muscle involvement in children with glycogen storage disease type III
verfasst von
Engy A. Mogahed
Marian Y. Girgis
Rodina Sobhy
Hala Elhabashy
Osama M. Abdelaziz
Hanaa El-Karaksy
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Pediatrics / Ausgabe 11/2015
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-015-2546-0

Weitere Artikel der Ausgabe 11/2015

European Journal of Pediatrics 11/2015 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.